Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04966676
Title Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.